To the best of our knowledge, this was the first study that the anti-ENO1 antibody combined with MET could reverse drug resistance with DDP or CTX by targeting both ALDH+ and CD44+ subpopulations by inhibiting the Wnt/β-catenin pathway in GC and NSCLC CSCs (Figs. 6A and 6B). Here, MET is linked to non-small cell lung carcinoma.